Investors

‍

genOway enters into an exclusive strategic distribution agreement with Taconic Biosciences to establish leadership in humanized models across the United States.

‍

• Taconic Biosciences, one of the leading US providers of preclinical research models, has a sales network covering the entire US market.
• Complementary offerings and customer bases provide strong opportunities to accelerate genOway’s sales, leading to a rapid impact in growth and profitability.
• The agreement has the potential to double genOway’s business in the United States, the world’s largest preclinical model market.

September 23, 2026: Download the press release

‍

‍

First-half 2026 results: 2028 revenue target of €50 million confirmed

‍

‍Strategy & outlook‍

• Accelerated growth in catalog products, with orders up by 20%
• Exclusive distribution agreement in the United States with Taconic Biosciences
• Gross margin in core businesses remains stable at 60% and is expected to continue in the second half of 2026

New strategic investments under the Route50+DATA plan

• Franchises and subsidiaries: initial positive commercial results, confirming multi-million-euro revenue targets for 2027
• DATA project (preclinical data and AI): R&D progress supports revenue generation objective in 2027

September 23, 2026: Download the press release

‍

‍

genOway continues its international expansion: launch of a “genOway Franchise” model with the opening of the first two franchises in Canada and Australia.

‍

• Dr. Nandita Noronha, exclusive genOway distributor in Canada
• Dr. Nathalie Taquet, exclusive genOway distributor in Australia
• Opening of ten genOway franchises targeted for 2026

April 14, 2026 : Download the press release

‍

‍

Strongfull-year 2025 results with an improved EBITDA margin of 21%

‍

• Successful rollout of the new commercial organization implemented in 2025, with a doubling of the sales team
• Operating profitability above the 15% minimum threshold set under the ROUTE50⁺ strategic plan

‍

Confirmation of the target for double-digit organic growth in 2026

‍

• Launch of two new Catalogue model ranges in inflammation and safety during the year
• Acceleration of international expansion, particularly in Asia, with growing activity from subsidiaries in China and Japan

March 30, 2026 : Download the press release

‍

‍

genOway continues its international expansion‍

‍

• Creation of its subsidiary genOway Japan to more effectively penetrate the world’s third-largest preclinical research market and
• Target €5–10 million in revenue as part of the Route50+ plan

March 25, 2026: Download the press release

‍

‍

Interview with Alexandre Fraichard:‘Bioaster will help us gain a year.’

‍

‍

• genOway achieved €21M in revenue in 2025 (-5%), impacted by a cautious market environment and a major commercial reorganization.
• The company accepts this slowdown in order to deploy its “Route 50+data” strategic plan and accelerate growth through the partial acquisition of Bioaster (13 hires).
• Profitability remains strong, with an EBITDA margin above 15% (16.9% in the first half of 2025), and operations in 28 countries serving 550 clients

‍

‍

The ROUTE50⁺ strategic plan becomes ROUTE50^+DATA with the acquisition of assets from anOMICS platform (data science & AI)

‍

• ROUTE50⁺ becomes ROUTE50^+DATA: genOway expands its strategic plan by integrating assets in data science, AI, and OMICS to enhance the predictability of preclinical data
• Financing & acceleration: the acquisition of these assets is financed by a €7 million private placement, enabling the plan to be accelerated by approximately one year with an operational platform planned for early 2026
• The company aims at an average organic growth of ~20% per year, at least €50 million in revenue by 2028, and an EBITDA margin > 15%

December 16, 2025 : Download the press release

‍

‍

Accelerated development in China: genOway Shanghai as a growth driver for the Group

‍

• The genOway Shanghai joint venture is rapidly accelerating its development in China, with growth well above initial forecasts.
• Its annualized revenue has approached ~€2 million in recent months and it is expected to reach profitability by the end of 2025
• The goal is to double revenue in 2026 and contribute between €5 million and €10 million to genOway's overall   revenue by 2028

November 18, 2025 : Download the press release

‍

‍

genOway Investor Presentation  

‍

September 25, 2025: Download the press release

‍

‍

‍

-----

‍

‍

‍

‍

‍

‍

‍